$ABSI News
Last published 2w ago
- 2w agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 3w agoHYFTAMDNVDAABSI+1AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.GlobeNewswireAUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of
- 4w agoHYFTGENBMRNAABSI+1AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestGlobeNewswireNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
- 4w agoABSIAbsci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026GlobeNewswireVANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 2mo agoHYFTTEMSDGRTWST+1AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030PR NewswireEquity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it....
- 2mo agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 2mo agoHYFTABCLABSILLY+1Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.GlobeNewswireNEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it
- 3mo agoHYFTAMDRXRXABSI+2A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is HeadedPR NewswireAmerican News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely watched...
- 3mo agoHYFTABSIABCLVKTX+1As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22PR NewswireEquity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical...
- 4mo agoABSIAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026GlobeNewswireVANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 4mo agoHYFTABSICERTAZN+1As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the ModelsPR NewswireUSA News Group News Commentary — A growing consensus in artificial intelligence holds that the models themselves are becoming interchangeable, and...
- 4mo agoABSIAbsci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial InvestorsGlobeNewswireEli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of
- 4mo agoABSIAbsci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)GlobeNewswireStudy medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval
- 4mo agoHYFTABSIRXRXSDGR+1The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItPR NewswireEquity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a...
- 5mo agoABSIHYFTMindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug DiscoveryBusiness WireMindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci
- 5mo agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 6mo agoABSIAbsci Reports Business Updates and First Quarter 2026 Financial and Operating ResultsGlobeNewswireSuccessfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE
- 6mo agoABSIAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 6mo agoABSIAbsci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026GlobeNewswireVANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 7mo agoABSIAbsci to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireVANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 7mo agoABSIAbsci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswireSuccessfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair
- 7mo agoABSIAbsci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo ClinicGlobeNewswireVANCOUVER, Wash. and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, announced
- 8mo agoABSIAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 8mo agoABSIAbsci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical OfficerGlobeNewswireFormer Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's
- 8mo agoABSIAbsci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026GlobeNewswireVANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
- 8mo agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the
- 11mo agoABSIAbsci to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireVANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the
- 11mo agoAMZNABSICERTSOPHAI Creation Engines Transform Biotech as Wellness Tech Captures Growth WavePR NewswireEquity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict...
- 11mo agoABSIAbsci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle MiniaturizationGlobeNewswireInhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201's potential to reverse follicular miniaturization and
- 11mo agoABSIAbsci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss ResearchGlobeNewswirePartnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci's upcoming Key Opinion
- 11mo agoABSIAbsci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic AlopeciaGlobeNewswireStudy to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for
- 12mo agoABSIAbsci Reports Business Updates and Third Quarter 2025 Financial and Operating ResultsGlobeNewswireReported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201
- 1y agoABSIAbsci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025GlobeNewswireVANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report
- 1y agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company
- 1y agoABSIAbsci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a TrialGlobeNewswireWebinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK,
- 1y agoABSIAMDORCLAbsci Accelerates AI-Driven Drug Discovery with Oracle and AMDGlobeNewswireAUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud
- 1y agoABSIAbsci Corporation (ABSI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoABSIAbsci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David GoldbergGlobeNewswireVANCOUVER, Wash. and NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced that world-renowned
- 1y agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the
- 1y agoABSIAbsci Corporation (ABSI) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoABSIAbsci Reports Business Updates and Second Quarter 2025 Financial and Operating ResultsGlobeNewswireStrengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded
- 1y agoABSIAlmirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology TargetGlobeNewswireAlmirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci's successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with
- 1y agoABSIAbsci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025GlobeNewswireVANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced
- 1y agoABSIAbsci Announces Pricing of Public Offering of Common StockGlobeNewswireVANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) ("Absci"), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today
- 1y agoABSIAbsci Announces Proposed Public Offering of Common StockGlobeNewswireVANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) ("Absci"), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI,
- 1y agoABSIATECILMNIRTC+1iRhythm Technologies Announces Board Member Retirements and New Director AppointmentsGlobeNewswireSAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today
- 1y agoABSIAbsci Appoints Biopharma Leader Mary Szela to Board of DirectorsGlobeNewswireVANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of
- 1y agoABSIAbsci to Participate in Upcoming Investor ConferencesGlobeNewswireVANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced
- 1y agoABSIAbsci Reports Business Updates and First Quarter 2025 Financial and Operating ResultsGlobeNewswireInitiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate
- 1y agoABSIAbsci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel DiseaseGlobeNewswireAbsci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement